Eye On ODAC: Former Members, FDA’s Pazdur Talk Pre-Meeting Mindsets, Impact Of Sponsor’s Experts

 
• By Sue Sutter

Oncologic Drugs Advisory Committee reps and the Oncology Center of Excellence director go behind the scenes to discuss FDA interactions with panelists, how opinions can change during a meeting, and why the voting question is important.

Behind the curtain
Current and former ODAC members, along with OCE Director Richard Pazdur, gave a behind-the-scenes look at the adcomm experience. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers